Início › Doença de Crohn › Carolina do Norte
Ensaios clínicos de Doença de Crohn em Carolina do Norte
20 estudos para Doença de Crohn estão buscando participantes em locais em Carolina do Norte.
Cidades em Carolina do Norte
Texto oficial do estudo (Inglês)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of North Carolina Medical Center ( Site 5034), Chapel Hill
- Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Digestive Health Partners /ID# 280490, Asheville
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
- Carolina Digestive Diseases, Greenville
- Piedmont Healthcare, Statesville
- e mais 1
RecrutandoFase 4
Idades de 18 a 80 · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina at Chapel Hill, Chapel Hill
- Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina, Chapel Hill
- Atrium Health, Charlotte
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
RecrutandoFase 3
Idades de 18 a 70 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- OnSite Clinical Solutions-Site Number: 8400051, Charlotte
- Duke University Medical Center-Site Number: 8400093, Durham
- e mais 3
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
- Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
RecrutandoFase 3
Idades de 16 a 80 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07184944A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Cross Creek Medical Clinic, Fayetteville
- Peters Medical Research, High Point
- Wake Research Associates, Raleigh
RecrutandoFase 2
Idades de 18 a 85 · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06226883A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- University of North Carolina at Chapel Hill, Chapel Hill
RecrutandoFase 4
Idades 18 e acima · Mulheres · Atualizado em 28 de ago. de 2026 · NCT07654751A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- University of North Carolina Hospital, Chapel Hill
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07577843Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of North Carolina, Chapel Hill
- Atrium Health Center for Gastroenterology and Surgery, Charlotte
- Wake Forest School of Medicine, Winston-Salem
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT07237516Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- University of North Carolina at Chapel Hill, Chapel Hill
Recrutando
Idades de 18 a 44 · Mulheres · Atualizado em 14 de jul. de 2026 · NCT07337902Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Univ NC Chapel Hill /ID# 262198, Chapel Hill
RecrutandoFase 3
Idades de 2 a 17 · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Levine Children's, Charlotte
RecrutandoFase 4
Idades de 6 a 17 · Todos os sexos · Atualizado em 27 de mai. de 2026 · NCT05781152COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health, Charlotte
- Duke Health System, Durham
RecrutandoEstudo observacional
Idades de 1 a 18 · Todos os sexos · Atualizado em 17 de abr. de 2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400003, Chapel Hill
RecrutandoFase 2
Idades de 18 a 75 · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, High Point
- Mirador Therapeutics Selected Site, Raleigh
RecrutandoFase 2
Idades de 18 a 80 · Todos os sexos · Atualizado em 12 de mar. de 2026 · NCT07113522Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Evidera, a PPD Business Unit /ID# 238688, Morrisville
RecrutandoEstudo observacional
Todas as idades · Mulheres · Atualizado em 17 de jul. de 2025 · NCT04846959Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.